CD274 and non-small cell lung carcinoma: In the phase II CITYSCAPE study (NCT03563716), tiragolumab combined with atezolizumab resulted in a clinically meaningful improvement in objective response rate, progression-free survival (PFS), and overall survival in the intent-to-treat population, driven by the PD-L1-high subgroup, compared with placebo combined with atezolizumab in the first-line setting for patients with metastatic non-small cell lung cancer (NSCLC) [11, 12].